MASSANO, DAVIDE
Dettaglio
MASSANO, DAVIDE
SCIENZE DELLA SANITA' PUBBLICA E PEDIATRICHE
Pubblicazioni
Risultati 1 - 14 di 14 (tempo di esecuzione: 0.001 secondi).
Titolo | Data di pubblicazione | Autore(i) | |
---|---|---|---|
1 | Clinical relevance of deferasirox trough levels in β-thalassemia patients | 2018 | Allegra, Sarah; Massano, Davide; De Francia, Silvia; Longo, Filomena; Piccione, Francesca; Pirro, Elisa; Cusato, Jessica; D'Avolio, Antonio; Piga, Antonio |
2 | Deferasirox AUC efficacy cutoff and role of pharmacogenetics | 2016 | Allegra, S; Cusato, J; De Francia, S; Massano, D; Piga, A; D'Avolio, A |
3 | Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients | 2017 | Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Arduino, Arianna; Massano, Davide; Longo, Filomena; Piga, Antonio; D'Avolio, Antonio |
4 | Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment | 2016 | Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio |
5 | Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients | 2017 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio |
6 | Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia | 2016 | Allegra, Sarah; De Francia, Silvia; Longo, Filomena; Massano, Davide; Cusato, Jessica; Arduino, Arianna; Pirro, Elisa; Piga, Antonio; D'Avolio, Antonio |
7 | Deferiprone | 2010 | A. Piga; S. Roggero; I. Salussolia; D. Massano; M. Serra; F. Longo |
8 | Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children | 2018 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio |
9 | The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients | 2019 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio |
10 | Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness | 2014 | Cusato, J; Allegra, S; Massano, D; De Francia, S; Piga, A; D'Avolio, A. |
11 | A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. | 2012 | De Francia S; Massano D; Piccione FM; Pirro E; Racca S; Di Carlo F; Piga A. |
12 | Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients | 2018 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio |
13 | Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes | 2018 | Allegra, Sarah; Cusato, Jessica; DE FRANCIA, Silvia; Arduino, A; Longo, Filomena; Pirro, Elisa; Massano, Davide; DE NICOLO', Amedeo; Piga, Antonio Giulio; D'Avolio, Antonio |
14 | Role of pharmacogenetics on deferasirox AUC and efficacy | 2016 | Cusato, Jessica; Allegra, Sarah; DE FRANCIA, Silvia; Massano, Davide; Piga, Antonio Giulio; D'Avolio, Antonio |